TY - JOUR
T1 - Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement
T2 - Insights from the Society of Thoracic Surgeons/American College of Cardiology National Cardiovascular Data Registry-Transcatheter Valve Therapy Registry
AU - Julien, Howard M.
AU - Stebbins, Amanda
AU - Vemulapalli, Sreekanth
AU - Nathan, Ashwin S.
AU - Eneanya, Nwamaka D.
AU - Groeneveld, Peter
AU - Fiorilli, Paul N.
AU - Herrmann, Howard C.
AU - Szeto, Wilson Y.
AU - Desai, Nimesh D.
AU - Anwaruddin, Saif
AU - Vora, Amit
AU - Shah, Binita
AU - Ng, Vivian G.
AU - Kumbhani, Dharam J.
AU - Giri, Jay
N1 - Publisher Copyright:
© 2021 American Heart Association, Inc.
PY - 2021
Y1 - 2021
N2 - Background: Reported rates of acute kidney injury (AKI) after transcatheter aortic valve replacement in small observational studies vary widely. Methods: Patients who underwent transcatheter aortic valve replacement in the United States between January 1, 2016 and June 30, 2018, were included. Patients without reported baseline or peak creatinine values and those who were previously on hemodialysis were excluded. AKI was defined using AKI Network criteria from stages 0 to 3. Logistic regression was used to assess patient and clinical factors associated with incident in-hospital AKI. Among patients with available data from the Center for Medicare and Medicaid Services administrative files, we compared 1-year mortality among patients with and without AKI. Results: Of 107 814 study patients, 11 566 (10.7%) experienced postprocedural AKI. Among patients who developed AKI, 10 220 (9.5%) experienced stage 1 AKI, 134 (0.1%) stage 2 AKI, and 1212 (1.1%) stage 3 AKI. Race, baseline comorbidities, clinical presentation, and procedural factors were associated with the development of stage 3 AKI. In Center for Medicare and Medicaid Services-linked analyses of 62 757 (58.2%) patients, those with AKI had higher adjusted hazard ratio for mortality at 1 year compared with patients who did not experience AKI (stage 1 AKI: adjusted hazard ratio, 2.7 [95% CI, 2.5-2.8], P<0.001; stage 2 AKI: adjusted hazard ratio, 10.4 [95% CI, 7.0-15.4], P<0.001; stage 3 AKI: adjusted hazard ratio, 7.0 [95% CI, 6.0-8.2], P<0.001). Conclusions: Using data from the Society of Thoracic Surgeons/American College of Cardiology National Cardiovascular Data Registry Transcatheter Valve Therapy Registry registry, we found that AKI is common after transcatheter aortic valve replacement, with over 10% of patients developing postprocedure AKI. Patients who developed stage 3 AKI had 7× higher adjusted 1-year mortality compared with patients who did not develop AKI.
AB - Background: Reported rates of acute kidney injury (AKI) after transcatheter aortic valve replacement in small observational studies vary widely. Methods: Patients who underwent transcatheter aortic valve replacement in the United States between January 1, 2016 and June 30, 2018, were included. Patients without reported baseline or peak creatinine values and those who were previously on hemodialysis were excluded. AKI was defined using AKI Network criteria from stages 0 to 3. Logistic regression was used to assess patient and clinical factors associated with incident in-hospital AKI. Among patients with available data from the Center for Medicare and Medicaid Services administrative files, we compared 1-year mortality among patients with and without AKI. Results: Of 107 814 study patients, 11 566 (10.7%) experienced postprocedural AKI. Among patients who developed AKI, 10 220 (9.5%) experienced stage 1 AKI, 134 (0.1%) stage 2 AKI, and 1212 (1.1%) stage 3 AKI. Race, baseline comorbidities, clinical presentation, and procedural factors were associated with the development of stage 3 AKI. In Center for Medicare and Medicaid Services-linked analyses of 62 757 (58.2%) patients, those with AKI had higher adjusted hazard ratio for mortality at 1 year compared with patients who did not experience AKI (stage 1 AKI: adjusted hazard ratio, 2.7 [95% CI, 2.5-2.8], P<0.001; stage 2 AKI: adjusted hazard ratio, 10.4 [95% CI, 7.0-15.4], P<0.001; stage 3 AKI: adjusted hazard ratio, 7.0 [95% CI, 6.0-8.2], P<0.001). Conclusions: Using data from the Society of Thoracic Surgeons/American College of Cardiology National Cardiovascular Data Registry Transcatheter Valve Therapy Registry registry, we found that AKI is common after transcatheter aortic valve replacement, with over 10% of patients developing postprocedure AKI. Patients who developed stage 3 AKI had 7× higher adjusted 1-year mortality compared with patients who did not develop AKI.
KW - Medicare
KW - kidney
KW - mortality
KW - percutaneous coronary intervention
KW - transcatheter aortic valve
UR - http://www.scopus.com/inward/record.url?scp=85104758473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104758473&partnerID=8YFLogxK
U2 - 10.1161/CIRCINTERVENTIONS.120.010032
DO - 10.1161/CIRCINTERVENTIONS.120.010032
M3 - Article
C2 - 33877860
AN - SCOPUS:85104758473
SN - 1941-7640
SP - 412
EP - 420
JO - Circulation: Cardiovascular Interventions
JF - Circulation: Cardiovascular Interventions
ER -